CD19 counts during RTX maintenance therapy do NOT perform well in assessing the risk of relapse Interestingly, only younger age was associated with relapse in this retrospective study @RheumNow #ACR25 Abst 1766 https://t.co/crsFKJ0LnP

• https://x.com/Dr_Brian_MD/status/1983197370197446827/photo/1

Can AI predict who stops their RA meds? In older adults on b/tsDMARDs, interpretable ML found frailty, comorbidity & age top the list for nonadherence risk. @RheumNow #ACR25 Abstract#2287

Girolami et al. VA study. Safety of DMARDs in RA following melanoma. 644 patients. 3 year all cause mortality. No significant difference, but graph sure looks like b/tsDMARDs are better. No melanoma specific mortality/recurrence data however. @RheumNow #ACR25 Abstr#2237 #ACRBest https://t.co/IN4LDkioT7

• https://x.com/RichardPAConway/status/1983195049287352507/photo/1

Is RA-ILD associated with/ higher risk of infection? Retrospective US cohort study 151 RA-ILD 980 matched controls 79% higher risk of any and pulmonary infections in RA-ILD Pathogen type: bacterial, viral and fungi Some of these infections are preventable! Take Home: https://t.co/fPmRjLL7Po

• https://x.com/AurelieRheumo/status/1983194685536375134/photo/1
• https://x.com/AurelieRheumo/status/1983194685536375134/photo/1

In DISCOVER-2, male PsA patients had greater radiographic progression than females despite similar baseline scores. Early joint response (W8 cDAPSA LDA) was linked to less progression more strongly in men. Highlights the sex differences in PsA outcomes. Abstract#2345 @RheumNow https://t.co/zIo59FYPVg

• https://x.com/synovialjoints/status/1983194545962570145/photo/1

Does specific ANCA subtype inform infectious risk? Retrospective review of 270 AAV patients revealed that about 1/3 pt developed severe infections... of these: - 64.1% MPO+ - 35.9% PR3+ Most infx during year 1 of tx No difference between CYC vs. RTX @RheumNow #ACR25 abst 2510

Simulation modeling by Patel et al helps generate probability of remission, relapse, and adverse events in newly dx AAV Projected risk by model were similar to observed rates in RCTs @RheumNow #ACR25 Abst 1764 https://t.co/xevkJ2Ih0M

• https://x.com/Dr_Brian_MD/status/1983189598806388769/photo/1
• https://x.com/Dr_Brian_MD/status/1983189598806388769/photo/1

HCQ weight-based dosing: out HCQ whole blood monitoring: in Whole blood levels more precisely balance risks of SLE flare (under-dosing) vs. toxicitiy (over-dosing) Many pt on <5 mg/kg had supra-therapeutic blood levels with risk for toxicity @RheumNow #ACR25 #ACRBest Abst 1722 https://t.co/qIbACxAW39

• https://x.com/Dr_Brian_MD/status/1983186074932482553/photo/1

Passive transfer of Ab can occur w #IVIg #Ab can occur from IVIg passive transfer incl HepB IVIg - if pt has #cryoglobulins 👇 Can precipitate severe #cryo flare #ClinicalPearl Secrets & Pearls session #ACR25 @RheumNow @ACRheum https://t.co/tTaSuVy1yQ

• https://x.com/Janetbirdope/status/1983176076089254137/photo/1

#1725 Functional NOTCH4 variants contribute to vasculopathy & fibrosis in SSc, particularly in African-American patients NOTCH4 hyperactivation disrupts angiogenesis & drives EndoMT; inhibition (including with FDA-approved Nirogacestat) restores vascular repair @RheumNow #ACR25

#1724 MAIT cells central in RA pathogenesis. These innate-like T cells accumulate in synovial fluid, driving fibroblast activation, cytokine release & joint damage. Blocking MAIT activation or deleting MR1 reduces arthritis in mice- a potential new target in RA. @RheumNow #ACR25

Pooled data fr diff SLE cohorts by Dr SGarg et al were evaluated to determine an upper threshold tx range of HCQ 750-1150 ng/mL: safe & effective HCQ levels >1150ng/mL-supratx, no added tx benefit CKD st >/=3: 2x ⬆️odds of toxic hcq levels #ACR25 @RheumNow Abs1722 #ACRBest https://t.co/RFx1VO0bov

• https://x.com/RHEUMarampa/status/1983164717398147083/photo/1
• https://x.com/RHEUMarampa/status/1983164717398147083/photo/1

#1723 Why is systemic autoimmunity more common in females? Loss of X-chromosome inactivation maintenance in B cells (not T cells) amplifies interferon-driven disease, with increased autoantibodies, inflammation and renal injury. Key mechanistic advance. @RheumNow #ACR25